摘要
有机阴离子转运多肽1B1(OATP1B1)是一种负责转运多种内外源性物质进入肝细胞发挥作用的摄入型转运蛋白。他汀类药物又称3-羟基-3-甲基戊二酸单酰辅酶A(HMG-CoA)还原酶抑制剂,临床上广泛应用于调脂及心脑血管疾病的预防,其疗效及不良反应有显著的个体化差异。研究表明OATP1B1基因多态性是导致他汀类药物个体化差异的重要因素。对OATP1B1基因多态性对他汀类药物影响的研究进展进行综述,为他汀类药物的个体化、安全化应用提供可能的理论指导。
OATP1B1 is a kind of uptake transporter which is responsible for transporting a variety of endogenous and exogenous substances into hepatocytes. Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A(HMG CoA) reductase inhibitors, are widely used in the prevention of lipid-lowering and cardiovascular and cerebrovascular diseases, with significant individual differences in efficacy and adverse reactions. Studies have shown that the OATP1B1 gene polymorphism is an important factor leading to individual differences in statins. The research progress on effect of OATP1B1 gene polymorphism on statins is reviewed in this article and to provide possible theoretical guidance for the individual and safe application of statins.
作者
薛阳
刘凯歌
XUE Yang;LIU Kai-ge(Xi’an Medical University,Xi’an 710021,China)
出处
《现代药物与临床》
CAS
2020年第4期820-824,共5页
Drugs & Clinic
